A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2018
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Cyclophosphamide; Epirubicin; Exemestane; Goserelin; Letrozole; Leuprorelin; Paclitaxel; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Sep 2017 Status changed from not yet recruiting to recruiting.
- 11 Sep 2017 New trial record